Vaxart announces $5 million Inavir® revenue milestone
Vaxart announced it received notification from Daiichi Sankyo that sales of Inavir®, a single dose product licensed in Japan to prevent or treat influenza infection, exceeded „20 billion in the fiscal year 2017, triggering a $5 million milestone payment to Vaxart. April 20, 2018